Unknown

Dataset Information

0

Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation.

ABSTRACT: A 72-year-old woman was referred to our hospital with Stage IV non-small-cell lung cancer (NSCLC). Chest computed tomography revealed a mass in the upper lobe of the right lung, with pleural effusion. Cytologic examination identified adenocarcinoma cells in the right pleural effusion. Furthermore, both a deletion mutation in exon 19 and a threonine-methionine substitution mutation at position 790 in exon 20 (T790M) were detected in the epidermal growth factor receptors (EGFR) in the malignant cells. As systemic chemotherapy consisting of carboplatin and pemetrexed or erlotinib proved ineffective, docetaxel monotherapy was initiated as a third-line treatment. Following salvage chemotherapy, her Eastern Cooperative Oncology Group performance status improved from 3 to 1, with tumor regression over 5 months. To the best of our knowledge, this is the first report of successful docetaxel treatment for a patient with NSCLC harboring the T790M EGFR-activating mutation identified before treatment with EGFR tyrosine kinase inhibitors.

SUBMITTER: Yamane H 

PROVIDER: S-EPMC3594004 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation.

Yamane Hiromichi H   Ochi Nobuaki N   Yasugi Masayuki M   Tabayashi Takayuki T   Yamagishi Tomoko T   Monobe Yasumasa Y   Hisamoto Akiko A   Kiura Katsuyuki K   Takigawa Nagio N  

OncoTargets and therapy 20130306

A 72-year-old woman was referred to our hospital with Stage IV non-small-cell lung cancer (NSCLC). Chest computed tomography revealed a mass in the upper lobe of the right lung, with pleural effusion. Cytologic examination identified adenocarcinoma cells in the right pleural effusion. Furthermore, both a deletion mutation in exon 19 and a threonine-methionine substitution mutation at position 790 in exon 20 (T790M) were detected in the epidermal growth factor receptors (EGFR) in the malignant ce  ...[more]

Similar Datasets

Unknown Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.
| S-EPMC4771182 | biostudies-literature
Unknown The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
| S-EPMC6288862 | biostudies-other
Unknown Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation.
| S-EPMC9156817 | biostudies-literature
Unknown Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer without harboring EGFR T790M mutation.
| S-EPMC7327692 | biostudies-literature
Unknown Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naive patients with non-small cell lung cancer harboring <i>EGFR</i> mutations.
| S-EPMC5620242 | biostudies-literature
Unknown Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer.
| S-EPMC4977654 | biostudies-other
Unknown Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.
| S-EPMC4830020 | biostudies-literature
Unknown EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation.
| S-EPMC7577810 | biostudies-literature
Unknown Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib.
| S-EPMC4429831 | biostudies-literature
Unknown Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer.
| S-EPMC8176237 | biostudies-literature